New drug shows promise against several aggressive cancers

February 13, 2019

Recently, a team of experts from The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust — both in the United Kingdom — has conducted a phase I/II clinical trial of a newly developed anticancer drug called tisotumab vedotin (TV).

To make the novel compound, scientists attached a toxic substance to an antibody that targets the “tissue factor” receptor, a protein that is abundant on the surface of numerous cancer cells and the presence of which predicts poor survival rates.

Read More on Medical News Today